Wednesday, February 11, 2026

10 AM ET/ 9 AM CT/ 8 AM MT/ 7 AM PT

Join us for an educational webinar focused on clinical trials and the  potential of NK cell therapy’s role in current myositis research.  Learn more about new emerging cell therapies from one of our community’s most trusted specialists – Dr. Lisa Christopher-Stine, MD, MPH, along with Dr. Shawn Rose, MD, PhD, Chief Medical Officer and Head of Research & Development, Nkarta Inc.  

Lisa Christopher-Stine, MD, MPH, Professor of Medicine and Neurology; Director of the Johns Hopkins Myositis Center 

In the intricate world of autoimmune disease, Dr. Lisa Christopher-Stine stands as a pillar of innovation, compassion, and scientific discovery. As a Professor of Medicine and Neurology at The Johns Hopkins University School of Medicine and the esteemed Director of the Johns Hopkins Myositis Center, she is a world-renowned leader whose work has fundamentally reshaped the understanding and treatment of inflammatory muscle diseases.

Dr. Christopher-Stine’s journey began with a distinguished academic foundation, graduating with honors from Franklin & Marshall College with induction into the Phi Beta Kappa Honor Society and earning her medical degree from Hahnemann University, where she was inducted into the prestigious Alpha Omega Alpha Honor Society. She further fortified her expertise with a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health and a subsequent rheumatology fellowship at Johns Hopkins, setting the stage for a career defined by excellence.

A true clinician-scientist, Dr. Christopher-Stine’s research has been nothing short of transformative. Her most significant contribution was the co-discovery of the anti-HMGCR autoantibody, which defined a new subtype of statin-associated immune-mediated necrotizing myopathy. This groundbreaking work created a new diagnostic paradigm, enabling clinicians worldwide to identify and treat patients who were previously misdiagnosed. Her prolific research, evidenced by an H-index of 61 and over 130 original publications, is anchored by her role as the principal investigator for the Johns Hopkins Myositis Research Registry—a global cohort of over 3,000 patients that serves as a vital resource for myositis studies.

Her leadership and influence are recognized through numerous accolades. She is consistently named one of America’s Top Doctors by Castle Connolly and was honored with The Arthritis Foundation’s Medical Champion Award. Alongside her team, she received The Myositis Association’s Medical Hero Award, a testament to their collective impact. Her international standing is further cemented by prestigious invitations such as, the Canadian Rheumatology Association Dunlop-Dottridge Lectureship, the Health Manpower Development Plan Visiting Expert from the Singapore Ministry of Health, and the Bilka Visiting Professorship at the Mayo Clinic.

Beyond her research, Dr. Christopher-Stine is a dedicated educator and a passionate advocate for patient-centered care. She co-chairs an international OMERACT initiative to develop patient-reported outcome measures, ensuring the patient perspective is integral to clinical trials. Patients describe her as a knowledgeable and deeply compassionate physician who, as one patient stated “cares about the whole me, not just my myositis.”

Through her visionary leadership of the Myositis Center, her pioneering research, and her unwavering dedication to her patients, Dr. Lisa Christopher-Stine is not just treating a disease; she is transforming lives and building a legacy of hope for the entire myositis community.

Shawn Rose, MD, PhD, Chief Medical Officer and Head of Research & Development, Nkarta Inc. 

Shawn Rose, MD, PhD, is Chief Medical Officer (CMO) and Head of Research & Development at Nkarta Inc. During his career, Dr. Rose has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu™, Stelara™ and Tremfya™.

As Chief Development Officer, Immunology at Vividion Therapeutics, Dr. Rose led the Vividion and Bayer strategy to advance a portfolio of novel immunology assets targeting previously undruggable proteins. As Senior Vice President and Head of the Clinical Development Organization at Magenta Therapeutics, he developed cell-based therapeutics for patients with cancer, genetic disorders, and autoimmune diseases. At Annexon Biosciences, he led autoimmunity clinical development.

Dr. Rose served as Senior Director of Immunology Translational Science and Medicine (TSM) at Johnson & Johnson (J&J), where he headed the clinical team responsible for the design and execution of early clinical studies. At J&J, he also served as the disease area strategic leader for rheumatology and autoimmunity within TSM, led a registrational program in systemic lupus erythematosus, and was Stelara compound development team leader for rheumatologic indications. Prior to joining J&J, Dr. Rose was at Bristol Myers Squibb (BMS), where he led clinical development programs as a director within BMS Immunoscience and co-chaired the Translational Research and Development Committee.

Dr. Rose was an attending physician at the NIH Clinical Center and volunteered at multiple community clinics in the Washington D.C. area. He completed his internal medicine residency and clinical and research fellowship in the Rheumatology Division at Northwestern University. Dr. Rose has been an R&D and corporate advisor to biotech companies and venture capital firms, helped to launch new biotech companies, and has served on multiple scientific advisory boards. He enjoys mentoring youth as well as the next generation of physicians, scientists, and biotech and pharmaceutical leaders in their career journey.